Related to JV Established to Develop mAb in China

• Kineta Inks Deals to Progress Antiviral and Autoimmune Programs
  
• Simcere Fortifies Stake in Chinese H1N1 Vaccine Firm to Over 50%
  
• Novartis to Invest $1.25B in Two New Facilities in China
  
• Novartis to Buy 85% of Chinese Vaccines Company for $125M
  
• Micromet Axes Alliance with MedImmune Regaining Rights to Clinical-Stage Cancer Drug
  
• Wanbang to Advance D-Pharm’s Late-Stage Stroke Therapy in China
  
• Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance
  
• PPD Acquires BioDuro to Further Expand Its Outsourcing Capabilities in China
  
• Merck Serono to Invest More than €150M in R&D Center in China
  
• Oxagen Raises £16M to Continue Clinical Development of CRTH2 Antagonist against Asthma
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Sinovac Expands Vaccine Capabilities with New JV
  
• Bayer Schering Pharma Receives Chinese Approval for MS Drug and Signs Anticancer Deal with Micromet
  
• Scientists Develop Method to Identify Molecules that Bind to Autoreactive T Cells
  
• AstraZeneca Provides $200M Up Front to Develop Targacept’s Late-Stage Candidate for Depression
  
• AstraZeneca’s Antidepressant Gets FDA Nod for Label Expansion
  
• Cambridge University and Chi-Med to Study Angiogenesis Effects of Chinese Medicinal Plants
  
• Investigators Find Genetic Basis to Clustering Effect Seen in Autoimmune Diseases
  
• OncoMethylome to Carry Out MGMT Assay as Part of Roche’s Phase III Avastin Trial in Glioblastoma
  
• f-star Raises $11.48M to Advance Antibody-Engineering Engine